BEIGF:OTCMKTS
BeOne Medicines
၂၁.၉၅ US$
၀.၀၀%
(၀.၀၀) 1D
၂၇.၀၄ US$
arrow_upward
+၂၃.၂၃% (+၅.၁၀)todayPre-market
Closed: ဇွန် ၉, GMT-၄ ၁၂:၄၉:၄၆ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
ဋေ ၄.၃၂ ထ
Avg. vol.
၀.၀၀
Volume
၁.၃၀ သိန်း
52-wk high
၂၄.၉၂ US$
52-wk low
၂၁.၉၅ US$
Beta
၀.၈၄
Shares outstanding
၁၄၂.၇၂ ဋေ
No. of employees
၁ သောင်း
Mkt. cap
ဋေ ၄.၃၂ ထ
Avg. vol.
၀.၀၀
Volume
၁.၃၀ သိန်း
52-wk high
၂၄.၉၂ US$
52-wk low
၂၁.၉၅ US$
Beta
၀.၈၄
Shares outstanding
၁၄၂.၇၂ ဋေ
No. of employees
၁ သောင်း
News stories
From web sources and news partners
MarketBeat
·
ပြီးခဲ့သည့် ၈ နာရီ
Sanders Morris Harris LLC Makes New Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၄ နာရီ
BeOne Medicines (ONC) Stock Trades Above Fair Value Following Its 103% Run
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees၁.၂ သောင်း
Founded၂၀၁၀ အောက် ၂၈
Headquarters-
Sector-
Websitebeonemedicines.com